Strategic merger Mirati Therapeutics is now part of Bristol Myers Squibb, presenting cross-selling and integration opportunities with BMS oncology portfolios, global sales channels, and expanded clinical development resources.

Financial scale With a funding base of 2.6B and modest revenue in the 10-25M range, there is potential to target collaborative research, co-development deals, or milestone-driven partnerships to accelerate late-stage programs.

Tech enabled Adoption of cloud and AI tools (Azure AI Services, SageMaker) alongside data platforms (Hotjar, Confluence) suggests readiness for advanced data collaboration, real-world evidence generation, and digital trial optimization partnerships.

Clinical momentum Recent high-profile activity around autoimmune CAR-T and manufacturing updates indicates opportunities for supply chain, CMC, and manufacturing analytics partnerships, as well as post-discovery process optimization services.

Market positioning Operating within biotechnology with a relatively small internal team, there is clear potential to offer CRO/CSO support, regulatory intelligence, and outsourced R&D services to scale development programs under BMS guidance.